Niitani Yoshie, Ohta Kouji, Yano Kanako, Kaneyasu Yoshino, Maehara Tomoko, Kitasaki Honami, Shigeishi Hideo, Nishi Hiromi, Nishimura Rumi, Naito Mariko, Shiba Fumie, Kawada-Matsuo Miki, Komatsuzawa Hitoshi, Takemoto Toshinobu
Department of Oral Health Management, Program of Oral Health Sciences, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima 734-8553, Japan.
Department of Public Oral Health, Program of Oral Health Sciences, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima 734-8553, Japan.
Dent J (Basel). 2025 Apr 8;13(4):160. doi: 10.3390/dj13040160.
Nisin A, an antimicrobial peptide produced by , primarily shows antimicrobial activity against Gram-positive bacteria, with efficacy increased when used in combination with an antimicrobial drug. On the other hand, oral candidiasis, caused by , occurs in immunocompromised patients and requires antifungal therapy. However, antifungal drug-resistant strains are increasing worldwide, leading to serious problems. To examine the effects of nisin A against species, we investigated the combined effects of nisin A and antifungal drugs on the growth and viability of strains. While nisin A alone had no antifungal effect, together with amphotericin (AMPH), it showed synergistic effects towards , as well as the non-albican strains , , and in checkerboard assay results. Furthermore, nisin A with miconazole (MCZ) or micafungin (MCFG) demonstrated a synergistic or additive effect on those strains. Cell viability assay results showed that nisin A enhanced the fungicidal activity of AMPH against both and . Biofilm reduction assays showed that nisin A with AMPH, MCZ, or MCFG inhibited biofilm activity against as compared with each antifungal drug alone. Finally, nisin A with AMPH, MCZ, or MCFG resulted in a reduced minimum inhibitory concentration of those antifungal drugs against clinically isolated and When used in combination with nisin A, the antifungal drug dosage can be lowered, thus helping to prevent adverse side effects and the emergence of drug-resistant oral species.
乳链菌肽A是由[具体产生菌]产生的一种抗菌肽，主要对革兰氏阳性菌表现出抗菌活性，与抗菌药物联合使用时效果增强。另一方面，由[具体病原菌]引起的口腔念珠菌病发生在免疫功能低下的患者中，需要抗真菌治疗。然而，全球范围内抗真菌耐药的[具体菌株]正在增加，导致严重问题。为了研究乳链菌肽A对[具体念珠菌属菌种]的影响，我们研究了乳链菌肽A与抗真菌药物联合对[具体念珠菌属菌种]菌株生长和活力的影响。虽然单独的乳链菌肽A没有抗真菌作用，但在棋盘法试验结果中，与两性霉素（AMPH）一起时，它对[白色念珠菌]以及非白色念珠菌菌株[近平滑念珠菌]、[热带念珠菌]和[光滑念珠菌]表现出协同作用。此外，乳链菌肽A与咪康唑（MCZ）或米卡芬净（MCFG）对这些菌株表现出协同或相加作用。细胞活力测定结果表明，乳链菌肽A增强了AMPH对[白色念珠菌]和[热带念珠菌]的杀菌活性。生物膜减少试验表明，与单独使用每种抗真菌药物相比，乳链菌肽A与AMPH、MCZ或MCFG联合使用可抑制对[白色念珠菌]的生物膜活性。最后，乳链菌肽A与AMPH、MCZ或MCFG联合使用导致这些抗真菌药物对临床分离的[白色念珠菌]和[热带念珠菌]的最低抑菌浓度降低。当与乳链菌肽A联合使用时，抗真菌药物的剂量可以降低，从而有助于预防不良副作用和耐药口腔[念珠菌属菌种]的出现。
需注意，原文中部分关键信息缺失（如产生菌、病原菌、具体念珠菌属菌种等），以上译文为尽量符合逻辑的补充翻译。
